Physician profile
Thomas B Choi
NPI 1477555985
$2,513.76
in general payments reported to CMS, 2019-2025
15 companies · $65.29 in 2025
The $65.29 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $51.79 · 2021: $292 · 2022: $410 · 2023: $187 · 2024: $31.68 · 2025: $65.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,335.72 | 2019 | |
| Beaver-Visitec International, INC. | $301.28 | 2022 | |
| Alcon Vision LLC | $257.55 | 2019-2023 | Clareon |
| Kala Pharmaceuticals, INC. | $188.52 | 2021 | |
| Bausch & Lomb Americas INC. | $111.99 | 2022-2025 | Envista Envy, Envista Mx60 Iol, Amvisc |
| Eyevance Pharmaceuticals LLC | $53.13 | 2021-2022 | |
| Henry Schein, INC. | $46.16 | 2025 | |
| Abbvie INC. | $44.31 | 2022-2023 | Xen Glaucoma Treatment System |
| Carl Zeiss Meditec USA, INC. | $44.01 | 2021 | |
| Glaukos Corporation | $34.09 | 2019 | |
| Ocular Therapeutix, INC. | $24.09 | 2019 | |
| Allergan, INC. | $20.25 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.